GlassScriptPhysician profile
Daniel P Kurz
NPI 1487097549
$3,321.32
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $223 · 2021: $2,515 · 2022: $242 · 2023: $84.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $84.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $84.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $2,205.00 | 2021 | |
| Biogen, INC. | $493.32 | 2019-2023 | Vumerity |
| Genzyme Corporation | $155.69 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $131.53 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $75.15 | 2021 | |
| Ucb, INC. | $38.22 | 2021 | |
| Csl Behring | $35.27 | 2020 | |
| Mallinckrodt Hospital Products INC. | $32.06 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $28.92 | 2021 | |
| Mallinckrodt Enterprises LLC | $27.84 | 2019 | |
| Merz North America, INC. | $27.02 | 2020 | |
| Grifols USA, LLC | $18.92 | 2019 | |
| Akcea Therapeutics, INC. | $18.80 | 2019 | |
| Acorda Therapeutics, INC | $17.50 | 2019 | |
| Glaxosmithkline, LLC. | $16.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kurz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.